China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the appointment of Dr. Mythili Koneru as its new Chief Medical Officer (CMO). In this role, Dr. Koneru will be responsible for leading the company’s clinical development and medical affairs programs, further strengthening Legend’s executive team.
Dr. Koneru’s Background and Experience
Dr. Koneru brings a wealth of experience to Legend Biotech, having previously served as CMO at US-based biotech Marker Therapeutics, where she led the development of immuno-oncology-focused cell therapies and therapeutic vaccines. Her academic credentials include a B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Biomedical Research: Tumor Immunology from New York University, and an M.D. from Robert Wood Johnson Medical School.
Strategic Expansion for Legend Biotech
The appointment of Dr. Koneru follows Legend Biotech’s recent establishment of a strategic advisory board in the United States, as reported last week. This move is part of the company’s strategic expansion and commitment to advancing its pipeline of innovative therapies. Legend Biotech is co-developing the BCMA-targeted chimeric antigen receptor (CAR) T cell therapy Carvykti (ciltacabtagene autoleucel; cilta-cel) with Janssen. The therapy received its first approval in the US in March 2022, and several other indications are currently under development, showcasing Legend’s dedication to transforming cancer treatment.-Fineline Info & Tech
